anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Vancomycin
Trial phase: Not Applicable
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 98
Group description: Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.

Vancomycin: Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
Eligibility criteria:
Inclusion Criteria:

deep brain stimulators (DBS)
spinal cord stimulators (SCS)
motor cortex stimulators (MCS)
vagus nerve stimulators (VNS)
peripheral nerve stimulators (PNS)

Exclusion Criteria:

allergies to vancomycin
immunocompromise or taking immunosuppressant drugs
currently taking aminoglycoside antibiotics, such as amikacin, gentamicin, neomycin, streptomycin or tobramycin
diagnosed renal failure
currently undergoing chemotherapy
pregnancy
non-english speakers
unable to return for follow-up, or unable to be contacted by telephone
Intervention: Fluciclatide
Trial phase: Phase 2
SMILES: NC(=O)COCC(=O)NCCOCCOCCOCCNC(=O)C1CSCC(=O)NC(CCCCNC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCNC(=O)CON=Cc2ccc(F)cc2)C(=O)NC2CSSCC(NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CCCN=C(N)N)NC2=O)C(=O)NC(Cc2ccccc2)C(=O)N1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 49
Group description: Fluciclatide Injection (AH111585 (18F) Injection)
Eligibility criteria:
Inclusion Criteria:

The subject has been diagnosed with at least one solid primary or metastatic tumor greater than 2.0 cm in diameter, including but not limited to NSCLC, RCC, GBM, melanoma, sarcoma, breast and H&N cancers.
The subject has received clinical routine imaging diagnostic work-up within 8 weeks prior to the first [18F]AH111585 PET scan.
The subject has a clinically acceptable (as judged by the investigator) physical examination at screening and is capable of self-care.

Exclusion Criteria:

The subject has known hyper- or hypo-coagulation syndromes.
The subject has received chemotherapy within 3 weeks, or received radiotherapy, surgery or any other treatment against cancer within 4 weeks prior to the first [18F]AH111585 PET scan.
The subject is scheduled to undergo chemotherapy, radiotherapy, surgery or any other treatment against cancer between the first and second [18F]AH111585 PET scans.
The subject is scheduled to undergo biopsy for the target tumour between the first and second [18F]AH111585 PET scans.
The subject has intra-hepatic tumour(s) only.
For the immuno-histochemistry group, the subject's target tumour has been biopsied less than or equal to 1 week prior to the first [18F]AH111585 PET scan.
Intervention: Atomoxetine
Trial phase: Phase 4
ATC code: N06BA09
SMILES: CNCC[C@@H](Oc1ccccc1C)c1ccccc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 27
Group description: atomoxetine alone
Eligibility criteria:
Inclusion Criteria:

meet DSM-IV diagnostic criteria for ADHD-combined type;
estimated IQ of 75 or higher;
agree to comply with the randomly assigned treatment condition;
enrolled in full time school at first grade level or higher; AND
have a primary teacher available to complete ratings for the entire study duration.

Exclusion Criteria:

current or past history of seizures (not including benign febrile seizures) or other neurological disorders;
physical conditions that preclude administration of Strattera or other medical illness that might confound study results or increase the safety risk to subjects exposed to study treatments (i.e. marked cardiac conduction delay, etc.);
prior failed trial of Strattera defined as 3 weeks or more on a daily dose of Strattera of at least .8mg/kg or a documented inability to tolerate at least .8mg/kg/day;
serious forms of psychopathology other than ADHD, such autism, bipolar disorder, schizophrenia or any other psychopathology requiring urgent treatment with psychotropic medication; OR
children for whom discontinuation of their current psychotropic medication would represent a serious risk to themselves or others.

The presence of Oppositional Defiant Disorder (ODD), Conduct Disorder (CD) or learning disabilities will not result in exclusion from the study as they are commonly occurring comorbidities that have not been found to moderate response to ADHD treatments (Jensen et al., 2001). Enrollment in special education services will also not be an exclusionary criteria as work by this research group has found that such services do not affect response to ADHD treatments (Niemic, Fabiano, Pelham, & Fuller, 2002).
Intervention: Citalopram
Trial phase: Phase 4
ATC code: N06AB04 | N06AB10
SMILES: CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: 12-week open label with 2 week placebo period (14 weeks total)

Escitalopram: 10mg tab daily
Eligibility criteria:
Inclusion Criteria:

Age: Two strata: 60-74 years (n=60) subjects and 75-84 years (n=60).
Diagnosis: Major depression, unipolar (by DSM-IV criteria); or, for control subjects, no diagnosis of major depression, no history of depression or other psychiatric conditions.
Severity of depression: A 24-Item HDRS above 19; Level of Executive Dysfunction: Two strata within each age stratum: Stroop Color-Word scores below and above 24 (1 SD below the median of our normal elderly sample).

Exclusion Criteria:

Psychotic depression by DSM-IV, i.e., presence of delusions with a score higher than 2 (questionable delusion) rated by the Scale for Assessment of Positive Symptoms (SAPS; 51).
High suicide risk, i.e. intent or plan to attempt suicide in near future.
Presence of any Axis I psychiatric disorder or substance abuse other than unipolar major depression.
Axis II diagnosis of antisocial personality (by SCID-P and DSM-IV).
History of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (bipolar disorder, hypomania, are exclusion criteria).
Cognition: MMSE scores below 24 or diagnosis of dementia by DSM-IV.
Acute or severe medical illness, i.e., delirium, metastatic cancer, decompensated cardiac, liver or kidney failure, major surgery, stroke or myocardial infarction during the three months prior to entry; or drugs known to cause depression, e.g., reserpine, alpha-methyl-dopa, steroids.
Failure to respond to an adequate trial of escitalopram (10 mg/day or more for 6 weeks or longer) during the current or previous depressive episodes.
Current involvement in psychotherapy.
History of hypersensitivity to escitalopram or need to receive drugs that may interact with escitalopram.
Inability to perform any of the ADLs (MAI: ADL subscale) even with assistance, e.g. walking with a cane is not an exclusion criterion.
Inability to speak English.
Aphasia.
Residence outside a 45-minute drive from Cornell's clinical facilities.
Patients taking MAOI's and Fluoxetine will be excluded.
Intervention: Healon
Trial phase: Phase 2
SMILES: CC(=O)NC1C(O)OC(CO)C(O)C1OC1OC(C(=O)O)C(OC2OC(CO)C(O)C(OC3OC(C(=O)O)C(O)C(O)C3O)C2NC(C)=O)C(O)C1O.[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
Eligibility criteria:
Inclusion Criteria:

were 18 years of age or older, reported unilateral ankle pain for at least 6 months and had either reported no significant benefit from conservative treatment (rest, physical therapy, orthoses or pain medications etc.) or were unable to tolerate side effects of medications
ankle radiographs taken within 6 months were equivalent to grade 2 or 3 according to the Kellgren-Lawrence grading system (grade 2, definite osteophytes and possible narrowing of joint space; grade 3, moderate multiple osteophytes, definite narrowing of joint space, some sclerosis and possible deformity of bone contour)22
had a current total AOS score (described below) of > 3 and < 9 (possible range, 0-10)
were normally active, not bedridden or confined to a wheelchair, and were able to walk 30 meters without the aid of a walker, crutches or cane
were willing to discontinue all nonsteroidal anti-inflammatory drugs (NSAIDs) or other analgesic medication (except for rescue medication) for the duration of the study
did not receive physical therapy or trial of shoe modifications or orthotics during the study period

Exclusion Criteria:

pregnant and lactating women
bilateral ankle OA requiring treatment of both ankles
chronic ankle instability
lower leg trauma other than within the ankle
previous orthopedic surgery on the spine, hip or knee
presence of active joint infections of foot or ankle
previous surgery or arthroscopy on the ankle within 12 months
intraarticular steroid or HA injection in the treated ankle within the past 6 months
treatment with anticoagulants or immunosuppressives
history of rheumatoid arthritis, gout, or any other inflammatory arthropathy
history of avian protein allergy
presence of other comorbidity (neoplasm, diabetes mellitus, paresis, recent trauma, etc) or poor health status that would interfere with the clinical assessments during the study
Intervention: Ethanol
Trial phase: Phase 2
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 69
Group description: 150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.
Eligibility criteria:
Inclusion Criteria:

female, 45 to 80 years of age, in good general health
postmenopausal ≥2 years, surgically or naturally
body mass index less than or equal to 32 kg/m^2 at screening

Exclusion Criteria:

no use within 3 months prior, nor use for more than 1 month at any time within 6 months of: glucocorticoids, anabolic steroids, estrogens, selective estrogen-receptor modulators (SERMs), or estrogen-related drugs, progestins, calcitonin, vitamin D supplements (>1200 IU per day), calcitriol, calcidiol, or alfacalcidol at any dose, any bisphosphonate. fluoride (≥10 mg/day), strontium (≥50 mg/day), parathyroid hormone, investigational bone active agents.
allergic or abnormal reactions to bisphosphonates
history of cancer within 5 years, excluding squamous and basal cell carcinoma with 6 month remission
positive pregnancy test
no depot injection >10,000 IU vitamin D in previous 9 months.
no history of GI disease that requires medication, or history of Crohn's disease, ulcerative colitis, diverticular disease, polyps, or surgery that could have changed GI structure or motility.
no history of frequent diarrhea or constipation that requires regular laxative use.
no history of alcohol or durg abuse, hyperparathyroidism, cancer previous 5 years, major surgery within 1 month prior to screening, diabetes, uncontrolled hypertension, cardiovascular, hepatic, renal or GI disease.
no active hyperthyroidism, osteomalacia, use of anticonvulsant medication, or allergic reaction to bisphosphonates
Intervention: Saxagliptin
Trial phase: Phase 3
ATC code: A10BD10 | A10BD21 | A10BD25 | A10BH03
SMILES: N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 107
Group description: Saxagliptin 5 mg tablet, once daily( OD) for 24 weeks
Eligibility criteria:
Inclusion Criteria:

Diagnosed with Type 2 diabetes
Patients should be drug naïve ie, not received medical treatment for diabetes
HbA1c ≥ 7.2% and ≤10.0% (at enrolment), HbA1c ≥ 7.0% and ≤10.0% (at randomization)

Exclusion Criteria:

Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)
Type 1 diabetes,history of ketoacidosis or hyperosmolar non-ketonic koma
Intervention: Chondroitin 4-sulfate
Trial phase: Phase 2
ATC code: M01AX25
SMILES: CC(=O)NC1C(O)OC(OS(=O)(=O)O)C(O)C1OC1OC(C(=O)O)C(O)C(O)C1O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 49
Group description: 2% sodium chondroitin sulfate

One subject was misrandomized. Actual treatment was used for Demographic and Safety analysis.
Eligibility criteria:
Inclusion Criteria:

Are a female, 18 years or older
Have been diagnosed with IC/PBS
Are willing to provide written informed consent and authorization to disclose after being fully informed of the risks of participation

Exclusion Criteria:

Are lactating females
Have previously received investigational products or devices within 30 days of screening
Have previously received Uracyst
Are currently receiving therapy with Interstim®
Have any other condition/disease which, in the opinion of the investigator, could compromise subject safety or confound the interpretation of study results
Are unable or unwilling to comply with protocol requirements
Intervention: OXYTOCIN
Trial phase: Phase 4
ATC code: H01BB02
SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Oxytocin, 40 IU intranasally, once

Oxytocin: A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
Eligibility criteria:
Inclusion Criteria:

19 - 65 years of age
Must meet the current National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) diagnostic criteria for interstitial cystitis and have some degree of continuous daily pain

Exclusion Criteria:

Pregnancy
Under the age of 19
Older that the age of 65
Breastfeeding women
Uncontrolled hypertension
History of significant cardiac or pulmonary disease (including arrhythmias)
Known allergy to oxytocin
Severe psychiatric disease
Patients who have undergone procedural interventions within the past month related to their interstitial cystitis
Intervention: Ubidecarenone
Trial phase: Phase 2
ATC code: C01EB09
SMILES: COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: All participants will start on a dosage of 600 mg/day of CoQ10 in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.

CoQ10: Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
Eligibility criteria:
Inclusion Criteria:

Participants will be positive for the CAGn expansion in the Huntingtin gene (>36 repeats) and be pre-manifest by virtue of scoring 3 or less on diagnostic confidence level (Question 17 of the UHDRS)
Participants will have received genetic testing prior to enrollment through a standard pre-manifest testing protocol.
18 years of age or older.
Concomitant medications are permitted with the exception of CoQ10, creatine > 5g/day and warfarin.

Exclusion Criteria:

History of intolerability to CoQ10.
CoQ10 use within 60 days prior to randomization.
Unstable medical or psychiatric illness;
Substance abuse within one year of the baseline visit.
Pregnancy, breastfeeding or lack of reliable contraception in women of childbearing age.
Subjects with known allergy to FD&C #6 yellow food coloring.
Intervention: Ubidecarenone
Trial phase: Phase 2
ATC code: C01EB09
SMILES: COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 29
Group description: All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.

CoQ10: Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
Eligibility criteria:
Inclusion Criteria:

Participants will be positive for the CAGn expansion in the Huntingtin gene (>36 repeats) and be pre-manifest by virtue of scoring 3 or less on diagnostic confidence level (Question 17 of the UHDRS)
Participants will have received genetic testing prior to enrollment through a standard pre-manifest testing protocol.
18 years of age or older.
Concomitant medications are permitted with the exception of CoQ10, creatine > 5g/day and warfarin.

Exclusion Criteria:

History of intolerability to CoQ10.
CoQ10 use within 60 days prior to randomization.
Unstable medical or psychiatric illness;
Substance abuse within one year of the baseline visit.
Pregnancy, breastfeeding or lack of reliable contraception in women of childbearing age.
Subjects with known allergy to FD&C #6 yellow food coloring.
Intervention: Ubidecarenone
Trial phase: Phase 2
ATC code: C01EB09
SMILES: COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 32
Group description: All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.

CoQ10: Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
Eligibility criteria:
Inclusion Criteria:

Participants will be positive for the CAGn expansion in the Huntingtin gene (>36 repeats) and be pre-manifest by virtue of scoring 3 or less on diagnostic confidence level (Question 17 of the UHDRS)
Participants will have received genetic testing prior to enrollment through a standard pre-manifest testing protocol.
18 years of age or older.
Concomitant medications are permitted with the exception of CoQ10, creatine > 5g/day and warfarin.

Exclusion Criteria:

History of intolerability to CoQ10.
CoQ10 use within 60 days prior to randomization.
Unstable medical or psychiatric illness;
Substance abuse within one year of the baseline visit.
Pregnancy, breastfeeding or lack of reliable contraception in women of childbearing age.
Subjects with known allergy to FD&C #6 yellow food coloring.
Intervention: Ceftazidime
Trial phase: Phase 2
ATC code: J01DD02
SMILES: CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CSC12)c1csc(N)n1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 42
Group description: Ceftazidime: intravenous 1000 mg every 8 hours
Eligibility criteria:
Inclusion Criteria:

Males and females 18 to 90 years of age, inclusive.
Pyuria (white blood cell [WBC] count > 10/µL in unspun urine or ≥ 10 per high power field in spun urine)

Clinical signs and/or symptoms of cUTI, either of:

a. Pyelonephritis, as indicated by both of the following: i. Fever (oral temperature ≥ 37.8°C); ii. Flank pain or costovertebral angle tenderness;

OR

b. Complicated lower UTI, as indicated by both of the following: i. At least one of the following new or worsening symptoms:

Dysuria;
Frequency;
Suprapubic pain;
Urgency

ii. At least one of the following complicating factors:

Male gender;
Current bladder instrumentation or indwelling urinary catheter that is expected to be removed during the course of IV study drug administration;
Obstructive uropathy that is expected to be medically or surgically treated during the course of IV study drug administration;
Urogenital surgery within 7 days preceding administration of the first dose of study drug;
Functional or anatomical abnormality of the urogenital tract including anatomic malformations or neurogenic bladder with voiding disturbance of at least 100 mL residual urine.

Exclusion Criteria

Documented history of any hypersensitivity or allergic reaction to any β-lactam antibacterial
Concomitant infection requiring systemic antibacterial therapy in addition to IV study drug therapy at the time of randomization. Drugs with only gram-positive activity (e.g. vancomycin, linezolid) are allowed
Complete, permanent obstruction of the urinary tract
Confirmed (at time of randomization) fungal urinary tract infection (with ≥ 103 fungal CFU/mL)
Suspected or confirmed perinephric or intrarenal abscess
Suspected or confirmed prostatitis
Known ileal loop or vesico-ureteral reflux
Women who are pregnant or nursing
Intervention: SODIUM BICARBONATE
Trial phase: Phase 2
ATC code: B05CB04 | B05XA02
SMILES: O=C([O-])O.[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 44
Group description: This arm two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.

Sodium Bicarbonate: Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
Eligibility criteria:
Inclusion Criteria:

elective, urgent, or emergent cardiac surgery using cardiopulmonary bypass
baseline GFR less than 60 ml/min/1.73m2 estimated using the Modification of Diet in Renal Disease equation

Exclusion Criteria:

cardiogenic shock (defined as a cardiac index less 2 L/min/m2 despite high dose inotropes or the need for intra-aortic balloon pump)
end-stage kidney disease requiring dialysis
received an infusion of sodium bicarbonate on the same day as cardiac surgery